Hirokazu Miyashita
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Hirokazu Miyashita has a total of 108 co-authors. Here are the top co-authors by number of shared publications:
Noriaki Moriyama
Department of Cardiology and Catheterization Laboratories, Shonan Kamakura General Hospital, Kamakura City, Japan
10 shared publicationsShigeru Saito
10 shared publicationsKoki Shishido
8 shared publications- Noriaki Moriyama
Department of Cardiology, Shonan Kamakura General Hospital, Kanagawa, Japan
8 shared publications - Yoichi Sugiyama
Department of Cardiology, Shonan Kamakura General Hospital , 1370-1 Kamakura Okamoto, Kamakura 2478533
8 shared publications Futoshi Yamanaka
7 shared publications
Latest Publications
- 14 September 2026
- Published by Wiley in Catheterization and Cardiovascular Interventions
- Vol. 108 (6) , 2035-2045
The JOKER Study: Jetstream Atherectomy for DebulKing of Calcified Femoropopliteal Artery Disease: Early Outcomes From a Multicenter Retrospective Study
Background: Endovascular therapy (EVT) for lower limb artery disease with severe calcification is challenging, as lesions may be unresponsive to balloon dilatation and may hinder full scaffold expansion. The Jetstream atherectomy device has been introduced to address these heavily calcified lower limb arterial lesions; however, its safety and effectiveness remain uncertain. This study aimed to evaluate the clinical outcomes of EVT using the Jetstream atherectomy device for severely calcified lesions. Methods: Patients who underwent treatment with the Jetstream system between November 2022 and October 2024 across four centers were enrolled (238 patients, 307 lesions). The safety outcome was a composite outcome that included cases of non‐recovered flow deterioration, intra‐procedural vessel perforation/rupture, and in‐hospital limb major amputation. The primary efficacy endpoint was the primary patency rate, and the secondary efficacy endpoint was clinically driven target lesion revascularization (CD‐TLR) at 1 year. Results: The mean patient age was 75.0 years; 31.9% were female, and 38.2% were receiving hemodialysis. The mean lesion length was 176.5 mm, and 63.2% of lesions demonstrated severe calcification (PACSS grade 4). Regarding device use, drug‐coated balloons (DCB) were applied in 95.4% of cases, whereas stents were implanted in 10 cases (3.3%). The safety composite endpoint occurred in 4.2%. The primary patency rate at 1 year was 83.8%, and freedom from CD‐TLR at 1 year was 91.1%. Multivariable analysis identified non–de novo lesions, occlusive lesions, smaller reference vessel diameter, and smaller maximum Jetstream device size as independent predictors of primary patency loss. In contrast, IVUS‐derived parameters assessed after DCB treatment were not associated with primary patency loss. Conclusion: Jetstream atherectomy demonstrated a safety profile comparable to that reported in previous atherectomy studies and was associated with favorable outcomes in severely calcified femoropopliteal lesions. These findings should be considered hypothesis‐generating.
- 14 September 2026
- Published by Wiley in Catheterization and Cardiovascular Interventions
- Vol. 108 (6) , 2035-2045
The JOKER Study: Jetstream Atherectomy for DebulKing of Calcified Femoropopliteal Artery Disease: Early Outcomes From a Multicenter Retrospective Study
Background: Endovascular therapy (EVT) for lower limb artery disease with severe calcification is challenging, as lesions may be unresponsive to balloon dilatation and may hinder full scaffold expansion. The Jetstream atherectomy device has been introduced to address these heavily calcified lower limb arterial lesions; however, its safety and effectiveness remain uncertain. This study aimed to evaluate the clinical outcomes of EVT using the Jetstream atherectomy device for severely calcified lesions. Methods: Patients who underwent treatment with the Jetstream system between November 2022 and October 2024 across four centers were enrolled (238 patients, 307 lesions). The safety outcome was a composite outcome that included cases of non‐recovered flow deterioration, intra‐procedural vessel perforation/rupture, and in‐hospital limb major amputation. The primary efficacy endpoint was the primary patency rate, and the secondary efficacy endpoint was clinically driven target lesion revascularization (CD‐TLR) at 1 year. Results: The mean patient age was 75.0 years; 31.9% were female, and 38.2% were receiving hemodialysis. The mean lesion length was 176.5 mm, and 63.2% of lesions demonstrated severe calcification (PACSS grade 4). Regarding device use, drug‐coated balloons (DCB) were applied in 95.4% of cases, whereas stents were implanted in 10 cases (3.3%). The safety composite endpoint occurred in 4.2%. The primary patency rate at 1 year was 83.8%, and freedom from CD‐TLR at 1 year was 91.1%. Multivariable analysis identified non–de novo lesions, occlusive lesions, smaller reference vessel diameter, and smaller maximum Jetstream device size as independent predictors of primary patency loss. In contrast, IVUS‐derived parameters assessed after DCB treatment were not associated with primary patency loss. Conclusion: Jetstream atherectomy demonstrated a safety profile comparable to that reported in previous atherectomy studies and was associated with favorable outcomes in severely calcified femoropopliteal lesions. These findings should be considered hypothesis‐generating.
- Open Access
- 1 September 2026
- Published by Elsevier in JACC: Asia
- Vol. 6 (9) , 2130-2132
Assessment of Implantation With Intra-Annular Self-Expandable Device in Transcatheter Aortic Valve Replacement
- 1 September 2026
- Published by Elsevier in JACC: Asia
- Vol. 6 (9) , 2130-2132
Open AccessAssessment of Implantation With Intra-Annular Self-Expandable Device in Transcatheter Aortic Valve Replacement
- 17 August 2026
- Published by Wiley in Catheterization and Cardiovascular Interventions
Successful Endovascular Revascularization of Aortoiliac Occlusive Disease With Favorable Outcome for Refractory Heart Failure After Axillary‐Bifemoral Bypass Surgery: A Case Report
Endovascular therapy for occlusive lesion might reduce cardiac afterload and improve cardiac function potentially, but there is limited evidence regarding its effects on heart failure, particularly in patients with poorly controlled symptoms. One month earlier, this 80‐year‐old woman with paroxysmal atrial fibrillation had undergone left axillo‐bifemoral bypass for acute aortoiliac occlusion and was transferred to a rehabilitation hospital. After that, she was returned to our hospital after developing palpitations, dyspnea, and hypoxia during post‐operative rehabilitation. Laboratory tests showed anemia, mild renal dysfunction, and markedly elevated B type natriuretic peptide. Chest radiography demonstrated bilateral pulmonary congestion. She was diagnosed to acute heart failure, and treatment with intravenous furosemide at a dose of 40 mg/day and oral amiodarone at a dose of 100 mg/day was initiated. Because sinus rhythm could not be maintained despite medical therapy and pulmonary vein isolation, atrioventricular node radiofrequency catheter ablation and cardiac resynchronization therapy pacemaker implantation were performed on hospital Day 12. However, exertional oxygen desaturation persisted, BNP remained elevated, and rehabilitation was limited by bilateral intermittent claudication. On hospital Day 22, endovascular therapy for aortoiliac occlusive disease was performed. Subsequently, additional endovascular therapy was undertaken for chronic total occlusion of the left superficial femoral artery. She was able to ambulate 20 m with support without any intermittent claudication (ankle‐brachial index increased from 0.67 to 0.91 on the right and from 0.81 to 0.98 on the left). Oxygen demand also gradually decreased (from 1 L/min to room air), and B type natriuretic peptide levels declined. Both systolic and diastolic blood pressure improved, and the patient was transferred back to the rehabilitation hospital on hospital Day 54 (32 days after endovascular therapy) without recurrence of heart failure symptoms. This case highlights two clinically relevant points. First, endovascular therapy for aortoiliac occlusive disease led to improvement in heart failure status. Second, B type natriuretic peptide levels showed a clear improvement following endovascular therapy.
- 17 August 2026
- Published by Wiley in Catheterization and Cardiovascular Interventions
Successful Endovascular Revascularization of Aortoiliac Occlusive Disease With Favorable Outcome for Refractory Heart Failure After Axillary‐Bifemoral Bypass Surgery: A Case Report
Endovascular therapy for occlusive lesion might reduce cardiac afterload and improve cardiac function potentially, but there is limited evidence regarding its effects on heart failure, particularly in patients with poorly controlled symptoms. One month earlier, this 80‐year‐old woman with paroxysmal atrial fibrillation had undergone left axillo‐bifemoral bypass for acute aortoiliac occlusion and was transferred to a rehabilitation hospital. After that, she was returned to our hospital after developing palpitations, dyspnea, and hypoxia during post‐operative rehabilitation. Laboratory tests showed anemia, mild renal dysfunction, and markedly elevated B type natriuretic peptide. Chest radiography demonstrated bilateral pulmonary congestion. She was diagnosed to acute heart failure, and treatment with intravenous furosemide at a dose of 40 mg/day and oral amiodarone at a dose of 100 mg/day was initiated. Because sinus rhythm could not be maintained despite medical therapy and pulmonary vein isolation, atrioventricular node radiofrequency catheter ablation and cardiac resynchronization therapy pacemaker implantation were performed on hospital Day 12. However, exertional oxygen desaturation persisted, BNP remained elevated, and rehabilitation was limited by bilateral intermittent claudication. On hospital Day 22, endovascular therapy for aortoiliac occlusive disease was performed. Subsequently, additional endovascular therapy was undertaken for chronic total occlusion of the left superficial femoral artery. She was able to ambulate 20 m with support without any intermittent claudication (ankle‐brachial index increased from 0.67 to 0.91 on the right and from 0.81 to 0.98 on the left). Oxygen demand also gradually decreased (from 1 L/min to room air), and B type natriuretic peptide levels declined. Both systolic and diastolic blood pressure improved, and the patient was transferred back to the rehabilitation hospital on hospital Day 54 (32 days after endovascular therapy) without recurrence of heart failure symptoms. This case highlights two clinically relevant points. First, endovascular therapy for aortoiliac occlusive disease led to improvement in heart failure status. Second, B type natriuretic peptide levels showed a clear improvement following endovascular therapy.
- Open Access
- 10 September 2025
- Published by Wiley in Catheterization and Cardiovascular Interventions
- Vol. 106 (5) , 3109-3119
Outcomes of Fluoroscopy‐Based Asymmetric Underexpansion With the Self‐Expanding ACURATE Neo and Neo2 Valve
Background: Asymmetric underexpansion of transcatheter heart valves (THVs), as observed on fluoroscopy, may influence prosthesis function or long‐term durability of transcatheter aortic valve implantation (TAVI). Aims: This study aimed to evaluate the effect of stent frame asymmetry on hemodynamic performance and clinical outcomes in ACURATE neo and neo2 THVs. Methods: In a retrospective registry, the TAVI asymmetry index was defined as the ratio of the THV stent frame diameter. Patients were divided into three groups based on this ratio: a tubular shape, TAVI asymmetry index < 10% (group 1); a tapered shape, a bottom diameter at least 10% greater than the upper diameter (group 2); and a flared shape, an upper diameter at least 10% greater than the bottom diameter (group 3). Impaired THV hemodynamic performance was defined as a mean residual THV gradient ≥ 20 mmHg and/or at least moderate paravalvular regurgitation. Results: From December 2015 to 2023, 585 patients were included (group 1, n = 447; group 2, n = 96; and group 3, n = 47). Compared to group 1, groups 2 and 3 exhibited a higher incidence of impaired THV hemodynamic performance (4.9% vs. 17.5% vs. 11.9%; p < 0.001). There was no significant difference in all‐cause mortality or heart failure hospitalization at 3 years among the three groups ( p = 0.787). In multivariable analysis, stent frame asymmetry (groups 2 and 3) was an independent predictor of impaired THV hemodynamic performance. Conclusions: Stent frame asymmetry of ACURATE neo and neo2 was associated with impaired THV hemodynamic performance but not with clinical outcomes.
- 10 September 2025
- Published by Wiley in Catheterization and Cardiovascular Interventions
- Vol. 106 (5) , 3109-3119
Open AccessOutcomes of Fluoroscopy‐Based Asymmetric Underexpansion With the Self‐Expanding ACURATE Neo and Neo2 Valve
Background: Asymmetric underexpansion of transcatheter heart valves (THVs), as observed on fluoroscopy, may influence prosthesis function or long‐term durability of transcatheter aortic valve implantation (TAVI). Aims: This study aimed to evaluate the effect of stent frame asymmetry on hemodynamic performance and clinical outcomes in ACURATE neo and neo2 THVs. Methods: In a retrospective registry, the TAVI asymmetry index was defined as the ratio of the THV stent frame diameter. Patients were divided into three groups based on this ratio: a tubular shape, TAVI asymmetry index < 10% (group 1); a tapered shape, a bottom diameter at least 10% greater than the upper diameter (group 2); and a flared shape, an upper diameter at least 10% greater than the bottom diameter (group 3). Impaired THV hemodynamic performance was defined as a mean residual THV gradient ≥ 20 mmHg and/or at least moderate paravalvular regurgitation. Results: From December 2015 to 2023, 585 patients were included (group 1, n = 447; group 2, n = 96; and group 3, n = 47). Compared to group 1, groups 2 and 3 exhibited a higher incidence of impaired THV hemodynamic performance (4.9% vs. 17.5% vs. 11.9%; p < 0.001). There was no significant difference in all‐cause mortality or heart failure hospitalization at 3 years among the three groups ( p = 0.787). In multivariable analysis, stent frame asymmetry (groups 2 and 3) was an independent predictor of impaired THV hemodynamic performance. Conclusions: Stent frame asymmetry of ACURATE neo and neo2 was associated with impaired THV hemodynamic performance but not with clinical outcomes.
- Open Access
- 20 July 2025
- Published by Springer Nature in Cardiovascular Intervention and Therapeutics
- Vol. 40 (4) , 1-12
Improvement in residual paravalvular leakage after transcatheter aortic valve replacement with a self-expanding valve: ACURATE neo2 versus ACURATE neo
The paravalvular leakage (PVL) incidence immediately after transcatheter aortic valve replacement (TAVR) is reportedly lower with ACURATE neo2 than with ACURATE neo. However, the difference in the subsequent PVL improvement between these valves and the improvement mechanism remain unclear. This study aimed to compare the incidence of and changes in the PVL between these valves and investigate the factors associated with PVL improvement. We included 403 patients who underwent TAVR with ACURATE neo2 (n = 134) or ACURATE neo (n = 269). The study endpoint was PVL improvement, defined as a reduction in the PVL grade from mild or higher at discharge to none/trace at 3 months. The PVL incidence of mild grade or higher was significantly lower with ACURATE neo2 than with ACURATE neo at 3 months (15.7% vs. 25.7%; p = 0.0234) but did not differ significantly at discharge (33.3% vs. 27.5%; p = 0.2291). A significant decrease in the PVL was observed only with ACURATE neo2 (p < 0.0001). Multivariate analysis demonstrated that ACURATE neo2 and calcium volume of the aortic leaflets were independent predictors of PVL improvement. The incidence of mild grade or higher PVL was lower with ACURATE neo2 than with ACURATE neo at 3 months due to the subsequent improvement. Patient selection focusing on leaflet calcification is important for preventing PVL because severe calcification impedes PVL improvement. Graphical abstract
- 20 July 2025
- Published by Springer Nature in Cardiovascular Intervention and Therapeutics
- Vol. 40 (4) , 1-12
Open AccessImprovement in residual paravalvular leakage after transcatheter aortic valve replacement with a self-expanding valve: ACURATE neo2 versus ACURATE neo
The paravalvular leakage (PVL) incidence immediately after transcatheter aortic valve replacement (TAVR) is reportedly lower with ACURATE neo2 than with ACURATE neo. However, the difference in the subsequent PVL improvement between these valves and the improvement mechanism remain unclear. This study aimed to compare the incidence of and changes in the PVL between these valves and investigate the factors associated with PVL improvement. We included 403 patients who underwent TAVR with ACURATE neo2 (n = 134) or ACURATE neo (n = 269). The study endpoint was PVL improvement, defined as a reduction in the PVL grade from mild or higher at discharge to none/trace at 3 months. The PVL incidence of mild grade or higher was significantly lower with ACURATE neo2 than with ACURATE neo at 3 months (15.7% vs. 25.7%; p = 0.0234) but did not differ significantly at discharge (33.3% vs. 27.5%; p = 0.2291). A significant decrease in the PVL was observed only with ACURATE neo2 (p < 0.0001). Multivariate analysis demonstrated that ACURATE neo2 and calcium volume of the aortic leaflets were independent predictors of PVL improvement. The incidence of mild grade or higher PVL was lower with ACURATE neo2 than with ACURATE neo at 3 months due to the subsequent improvement. Patient selection focusing on leaflet calcification is important for preventing PVL because severe calcification impedes PVL improvement. Graphical abstract
- Open Access
Clinical and hemodynamic outcomes for transcatheter aortic valve implantation in internally stented surgical valve -Comparison of Balloon- and Self-Expandable Valves-
Background: Valve-in-valve (ViV) transcatheter aortic valve implantation (TAVI) is indicated in patients undergoing repeat interventions for degenerative aortic valve bioprostheses. Patients with internally stented surgical valves (IS) (Mitroflow and Trifecta) are at a high risk for coronary artery obstruction during the ViV procedure. This study aimed to evaluate the mid-term clinical and hemodynamic outcomes of balloon-expandable valves (BEV) and supra-annular self-expanding valves (SEV) for TAVI within the IS. Methods: Baseline characteristics, hemodynamic parameters, and clinical outcomes of patients who underwent ViV for IS treated with BEV and SEV were retrospectively collected. Outcomes were compared using propensity score matching (PSM). Results: In total, 113 patients were included this analysis. Sixty-three patients (55.8%) underwent BEV, and fifty patients (44.2%) underwent SEV. Overall, 37 pairs were identified after PSM. At 30-day, the clinical and hemodynamic outcomes were similar between the groups. Patients with SEV had better post-procedural mean gradient at 1-year compared with those with BEV (22.7±8.4 mmHg vs 11.7±4.3 mmHg; p<0.001). There was no significant difference between SEV and BEV in the cumulative 2-year composite endpoint, including all-cause of mortality, hospitalization for heart failure, and coronary obstruction (log-rank p=0.489) Conclusions: In patients who underwent ViV for IS, the early- and mid-term clinical outcomes were comparable between BEV and SEV. Meanwhile, the 1-year hemodynamics seemed to be better in patients with SEV than in those with BEV. Clinical Perspective: What is new? Mid-term clinical outcomes, including all-cause mortality, heart failure rehospitalization, and coronary obstruction, were similar between balloon-expandable valve (BEV) and self-expanding valve (SEV) in valve-in-valve transcatheter aortic valve implantation (ViV-TAVI) for internally stented surgical valves (IS). SEV group has lower transvalvular gradients at 1-yearfollow-up than BEV group, while the occurrence of coronary obstruction were similar. What are the Clinical Implications? Individualized device selection and improving pre-operative screening for a risk of coronary obstruction, patient-specific anatomical and procedural factors can help the better clinical outcomes.
Open AccessClinical and hemodynamic outcomes for transcatheter aortic valve implantation in internally stented surgical valve -Comparison of Balloon- and Self-Expandable Valves-
Background: Valve-in-valve (ViV) transcatheter aortic valve implantation (TAVI) is indicated in patients undergoing repeat interventions for degenerative aortic valve bioprostheses. Patients with internally stented surgical valves (IS) (Mitroflow and Trifecta) are at a high risk for coronary artery obstruction during the ViV procedure. This study aimed to evaluate the mid-term clinical and hemodynamic outcomes of balloon-expandable valves (BEV) and supra-annular self-expanding valves (SEV) for TAVI within the IS. Methods: Baseline characteristics, hemodynamic parameters, and clinical outcomes of patients who underwent ViV for IS treated with BEV and SEV were retrospectively collected. Outcomes were compared using propensity score matching (PSM). Results: In total, 113 patients were included this analysis. Sixty-three patients (55.8%) underwent BEV, and fifty patients (44.2%) underwent SEV. Overall, 37 pairs were identified after PSM. At 30-day, the clinical and hemodynamic outcomes were similar between the groups. Patients with SEV had better post-procedural mean gradient at 1-year compared with those with BEV (22.7±8.4 mmHg vs 11.7±4.3 mmHg; p<0.001). There was no significant difference between SEV and BEV in the cumulative 2-year composite endpoint, including all-cause of mortality, hospitalization for heart failure, and coronary obstruction (log-rank p=0.489) Conclusions: In patients who underwent ViV for IS, the early- and mid-term clinical outcomes were comparable between BEV and SEV. Meanwhile, the 1-year hemodynamics seemed to be better in patients with SEV than in those with BEV. Clinical Perspective: What is new? Mid-term clinical outcomes, including all-cause mortality, heart failure rehospitalization, and coronary obstruction, were similar between balloon-expandable valve (BEV) and self-expanding valve (SEV) in valve-in-valve transcatheter aortic valve implantation (ViV-TAVI) for internally stented surgical valves (IS). SEV group has lower transvalvular gradients at 1-yearfollow-up than BEV group, while the occurrence of coronary obstruction were similar. What are the Clinical Implications? Individualized device selection and improving pre-operative screening for a risk of coronary obstruction, patient-specific anatomical and procedural factors can help the better clinical outcomes.
- 8 January 2025
- Published by Elsevier in JACC: Cardiovascular Interventions
- Vol. 18 (4) , 492-502
Incidence and Prognosis of Prosthesis-Patient Mismatch After Transcatheter Aortic Valve Replacement for Bicuspid Aortic Stenosis
- 8 January 2025
- Published by Elsevier in JACC: Cardiovascular Interventions
- Vol. 18 (4) , 492-502
Incidence and Prognosis of Prosthesis-Patient Mismatch After Transcatheter Aortic Valve Replacement for Bicuspid Aortic Stenosis
- Open Access
- 1 January 2025
- Published by SelSistem in Journal of Surgery and Medicine
- Vol. 9 (1) , 00
A case of brachial artery pseudoaneurysm requiring endovascular therapy twice
Brachial artery pseudoaneurysm (BAP) is a complication that can result from trauma, iatrogenic injury, or drug abuse, and can have serious consequences for the limb and overall health, including hemorrhage, nerve injury, venous edema, loss of limb function, and rupture. This paper describes a case of BAP that developed following the first hemostasis procedure and required a second endovascular therapy (EVT) procedure. The patient in this case had an iatrogenic brachial artery pseudoaneurysm (BAP) that appeared 10 days after coronary angiography. The patient experienced swelling and pain in the left upper limb, prompting emergency hemostasis with EVT. Percutaneous thrombin injection was administered, along with balloon inflation, and angiography confirmed successful hemostasis. However, 16 days after the initial EVT, the patient returned to the hospital with the same symptoms, and a recurrence of BAP was observed on duplex ultrasound. Stent graft implantation was required due to vessel structure disruption detected by intravascular ultrasound imaging. Following stent graft deployment, a final angiogram showed that the pseudoaneurysm had disappeared, and the patient experienced no complications for three months. This case highlights the importance of observing vascular structure with intravascular ultrasonography (IVUS) to predict successful hemostasis, and suggests that additional therapy should be considered when the structure is disrupted.
- 1 January 2025
- Published by SelSistem in Journal of Surgery and Medicine
- Vol. 9 (1) , 00
Open AccessA case of brachial artery pseudoaneurysm requiring endovascular therapy twice
Brachial artery pseudoaneurysm (BAP) is a complication that can result from trauma, iatrogenic injury, or drug abuse, and can have serious consequences for the limb and overall health, including hemorrhage, nerve injury, venous edema, loss of limb function, and rupture. This paper describes a case of BAP that developed following the first hemostasis procedure and required a second endovascular therapy (EVT) procedure. The patient in this case had an iatrogenic brachial artery pseudoaneurysm (BAP) that appeared 10 days after coronary angiography. The patient experienced swelling and pain in the left upper limb, prompting emergency hemostasis with EVT. Percutaneous thrombin injection was administered, along with balloon inflation, and angiography confirmed successful hemostasis. However, 16 days after the initial EVT, the patient returned to the hospital with the same symptoms, and a recurrence of BAP was observed on duplex ultrasound. Stent graft implantation was required due to vessel structure disruption detected by intravascular ultrasound imaging. Following stent graft deployment, a final angiogram showed that the pseudoaneurysm had disappeared, and the patient experienced no complications for three months. This case highlights the importance of observing vascular structure with intravascular ultrasonography (IVUS) to predict successful hemostasis, and suggests that additional therapy should be considered when the structure is disrupted.
- 10 September 2024
- Published by Oxford University Press (OUP) in European Heart Journal - Cardiovascular Imaging
- Vol. 26 (1) , 107-117
Difference in cardiac response after transcatheter aortic valve implantation according to flow and gradient pattern
Aims: In patients undergoing transcatheter aortic valve implantation (TAVI) for severe aortic stenosis (AS), data on the differences in subsequent cardiac structure and function among stratified groups with flow gradient patterns through the aortic valve are insufficient. Methods and results: In this large multicenter study, 4523 patients undergoing TAVI for severe AS between 2013 and 2019 were divided into three groups according to the following criteria: (i) high-gradient AS (HG-AS) [mean pressure gradient (MPG) ≥ 40 mmHg], (ii) classical low-flow low-gradient AS (cLFLG-AS) [MPG < 40 mmHg, left ventricular (LV) ejection fraction (LVEF) <50%], and (iii) paradoxical low-flow low-gradient AS (pLFLG-AS) [MPG < 40 mmHg, LVEF ≥ 50% but stroke volume index (SVi) <35 mL/m2]. Echocardiography was performed at baseline, post-procedure, and 1 year post-TAVI. 3697, 507, and 319 patients had HG-AS, cLFLG-AS, and pLFLG-AS, respectively. After adjusting for clinical factors, cLFLG-AS and pLFLG-AS had an ∼1.5-fold higher 2-year all-cause mortality compared with HG-AS. During 1 year following TAVI, compared with HG-AS, cLFLG-AS showed greater reduction of LV systolic diameter (LVDs) and LV diastolic diameter (LVDd) and greater increase of LVEF (P < 0.001 for all), and changes in LV mass index (LVMi) and SVi were comparable (P = 0.915 and P = 0.821, respectively). However, pLFLG-AS demonstrated less reduction of LVDs and LVDd (P = 0.039 and P = 0.001, respectively), less improvement of LVEF and LVMi (P = 0.045 and P < 0.001, respectively), and comparable change in SVi (P = 0.364). Conclusion: During 1 year post-TAVI, compared with HG-AS, cLFLG-AS achieves smaller LV diameters, greater increase in LVEF, and comparable regression of LVMi, whereas pLFLG-AS does not.
- 10 September 2024
- Published by Oxford University Press (OUP) in European Heart Journal - Cardiovascular Imaging
- Vol. 26 (1) , 107-117
Difference in cardiac response after transcatheter aortic valve implantation according to flow and gradient pattern
Aims: In patients undergoing transcatheter aortic valve implantation (TAVI) for severe aortic stenosis (AS), data on the differences in subsequent cardiac structure and function among stratified groups with flow gradient patterns through the aortic valve are insufficient. Methods and results: In this large multicenter study, 4523 patients undergoing TAVI for severe AS between 2013 and 2019 were divided into three groups according to the following criteria: (i) high-gradient AS (HG-AS) [mean pressure gradient (MPG) ≥ 40 mmHg], (ii) classical low-flow low-gradient AS (cLFLG-AS) [MPG < 40 mmHg, left ventricular (LV) ejection fraction (LVEF) <50%], and (iii) paradoxical low-flow low-gradient AS (pLFLG-AS) [MPG < 40 mmHg, LVEF ≥ 50% but stroke volume index (SVi) <35 mL/m2]. Echocardiography was performed at baseline, post-procedure, and 1 year post-TAVI. 3697, 507, and 319 patients had HG-AS, cLFLG-AS, and pLFLG-AS, respectively. After adjusting for clinical factors, cLFLG-AS and pLFLG-AS had an ∼1.5-fold higher 2-year all-cause mortality compared with HG-AS. During 1 year following TAVI, compared with HG-AS, cLFLG-AS showed greater reduction of LV systolic diameter (LVDs) and LV diastolic diameter (LVDd) and greater increase of LVEF (P < 0.001 for all), and changes in LV mass index (LVMi) and SVi were comparable (P = 0.915 and P = 0.821, respectively). However, pLFLG-AS demonstrated less reduction of LVDs and LVDd (P = 0.039 and P = 0.001, respectively), less improvement of LVEF and LVMi (P = 0.045 and P < 0.001, respectively), and comparable change in SVi (P = 0.364). Conclusion: During 1 year post-TAVI, compared with HG-AS, cLFLG-AS achieves smaller LV diameters, greater increase in LVEF, and comparable regression of LVMi, whereas pLFLG-AS does not.
- Open Access
- 25 March 2024
- Published by Japanese Circulation Society in Circulation Journal
- Vol. 88 (4) , 462-471
Long-Term Assessment of Survival After Transcatheter Aortic Valve Implantation ― Insights From the International Transcatheter Aortic Valve Implantation Registry ―
Background: Transcatheter aortic valve implantation (TAVI) is an established treatment for severe aortic stenosis (AS), but despite estimates of life expectancy after TAVI being essential in heart team discussion, these data are scarce. Therefore, the current study sought to assess long-term survival and its trends in relation to chronological age, surgical risk, and treatment period.Methods and Results: We included 2,414 consecutive patients who underwent TAVI for severe symptomatic AS between 2008 and 2021 at 2 international centers. For the analysis, long-term survival was evaluated according to age, surgical risk, and treatment period categorized into 3 groups, respectively. The longest follow-up was 13.5 years. Overall survival was 67.6% at 5 years and 26.9% at 10 years. Younger patients, lower surgical risk, and later treatment period showed better survival (log-rank P<0.001, respectively). In the multivariate analysis, age <75years, lower surgical risk, and later time period were significantly associated with better survival. The incidence of paravalvular leakage ≥moderate, red blood cell transfusion, and acute kidney injury were independently associated with increasing risk of 5-year death.Conclusions: In a real-world registry, survival was substantial following TAVI, especially in younger and lower surgical-risk patients, with improving outcomes over time. This should be considered in heart team discussions of life-long management for AS patients after TAVI.
- 25 March 2024
- Published by Japanese Circulation Society in Circulation Journal
- Vol. 88 (4) , 462-471
Open AccessLong-Term Assessment of Survival After Transcatheter Aortic Valve Implantation ― Insights From the International Transcatheter Aortic Valve Implantation Registry ―
Background: Transcatheter aortic valve implantation (TAVI) is an established treatment for severe aortic stenosis (AS), but despite estimates of life expectancy after TAVI being essential in heart team discussion, these data are scarce. Therefore, the current study sought to assess long-term survival and its trends in relation to chronological age, surgical risk, and treatment period.Methods and Results: We included 2,414 consecutive patients who underwent TAVI for severe symptomatic AS between 2008 and 2021 at 2 international centers. For the analysis, long-term survival was evaluated according to age, surgical risk, and treatment period categorized into 3 groups, respectively. The longest follow-up was 13.5 years. Overall survival was 67.6% at 5 years and 26.9% at 10 years. Younger patients, lower surgical risk, and later treatment period showed better survival (log-rank P<0.001, respectively). In the multivariate analysis, age <75years, lower surgical risk, and later time period were significantly associated with better survival. The incidence of paravalvular leakage ≥moderate, red blood cell transfusion, and acute kidney injury were independently associated with increasing risk of 5-year death.Conclusions: In a real-world registry, survival was substantial following TAVI, especially in younger and lower surgical-risk patients, with improving outcomes over time. This should be considered in heart team discussions of life-long management for AS patients after TAVI.